May 2021- Global Life Science Business Partnering - News & Updates

Highlights of May 2021

  1. Dyadic announced development of COVID-19 Vaccine in India, in collaboration with Syngene International Ltd.
  2. Aknamed acquires Vardhman Health Specialties for USD 35 Million.
  3. Strides Pharma partners with Nasdaq listed TLC to launch Liposomal Amphotericin B.
  4. Pregene and Dr. Reddy's Announce License Agreement for Anti-BCMA CAR-T PRG1801 in India.
  5. Lilly signs agreements with Cipla, Lupin, Torrent Pharma, BDR Pharma, MSN Labs , Natco Pharma and Sun Pharma for Baricitinib.
  6. Pharma major Biocon has tied up with Sri Anand Life Sciences to manufacture the life-saving drug at Belagavi.
  7. CytoDyn Signs Distribution Agreement with Macleods Pharmaceuticals Ltd. to Pursue EUA and Compassionate Use Access to Leronlimab in India.
  8. Zydus Cadila, Taiwan's TLC ink pact to market anti-black-fungus drug in India.
  9. NeoGenomics to acquire Inivata for $390M after success of lung cancer liquid biopsy collab.
  10. Sumitomo Dainippon acquires Asian rights for Sinovant compounds.
  11. CRISPR Therapeutics inks deal with Nkarta on gene-edited cell therapies for cancer.
  12. Amryt Pharma buying Chiasma, to create rare diseases powerhouse.

Highlights at Aagami: 

  1. New Win: Midwest US based Pharma with First-in-Class Non-Opioid Analgesic for Pain Relief.
  2. Extensions: Two Existing clients extended their contracts with Aagami, resulting from the professional support and encouraging results.
  3. Aagami now has boots on the ground in China, Europe and UK through strategic alliances.
  4. Aagami has 35+ one-on-one strategic meetings already scheduled at BIO Digital International. Calendar is open for more, by leveraging Aagami’s global presence enabling a wide time window.

NFOCUS: Select opportunities available at Aagami:

For Acquisition/Licensing:

  1. Mountain View Pharma (MVP) including its PharmaPEG® technology, product candidates, data package, & IP - Information Memorandum is available for review.    
  2. Patented Docetaxel and Complex Generic Doxorubicin – Few Data room diligence and Term Sheet level conversations going on.

For Investment/Partnering/Licensing:

  1. Series C: Seeking US$30M + - US Innovator bringing Confluence of Portable MRI, Robotics & AI in a Physician's Office. US FDA 510K approved. US$33M already raised. Existing investors include ZEPP, Philip Dolan, Kineticos, and MicroPort.
  2. Lidocaine 10% Topical Patch; NDA accepted by US FDA in Oct 2020 (Licensing for US available) – Ideal for Pharma companies and also wholesalers/distributors.
  3. Seeking US$5M for our client’s botanical drug candidate (NFL-101) without nicotine for smoking cessation. It is delivered subcutaneously, twice, one week apart.
  4. Opportunity to invest in Portable Point-Of-Care MRI for Neuro Imaging and Interventions.
  5. Series A $25M Financing: Midwest US based Pharma’s First-in-Class Non-Opioid Analgesic for Pain Relief – Seeking funding and partnerships.

      On the market product for Licensing:

  1. On the Market Pro-immunity supplement capsules of Rapid and synchronized dormancy-broken (awakened) Kyoho grape seed endosperm from our Japanese client.
  2. Japanese High Precision-Surface Plasmon Resonance (HP-SPR) Cells Screening by laser within 1 hour. 10,000 to 1Million times higher sensitivity compared to existing commercial instruments.
×
Twitter